会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • 벤족사진의 제조 방법
    • Ben照片的制作方法
    • KR1020170077200A
    • 2017-07-05
    • KR1020177014458
    • 2015-10-22
    • 사이텍 인더스트리스 인코포레이티드
    • 굽타,램비.코헨,마틴굽타,마나브
    • C07D265/16C07C211/47C07C39/24C07C315/04C07C317/36C08G73/02
    • C07D265/16C07C315/04C07C317/36C07D413/10C07D413/14
    • 적어도하나의 1차아미노기를함유하는방향족아민, 적어도하나의오르토수소를가진적어도하나의페놀계화합물, 및알킬포름셀로부터적어도하나의벤족사진단위를함유하는벤족사진화합물을제조하는합성법. 한양태에따르면, 방향족아민은알킬포름셀과반응하여알콕시메틸중간체화합물을생산한다. 이어서, 중간체화합물은페놀과반응하여벤족사진화합물을생산한다. 다른양태에따르면, 벤족사진화합물은방향족아민을알킬포름셀및 페놀과 1 반응단계으로반응시킴으로써형성된다. 또한, 방향족아민을알킬포름셀과반응시켜형성된알콕시메틸화합물을분리하는방법도개시된다. 분리된알콕시메틸화합물은후속반응의반응물로써유용하다.
    • 用于生产合成升方法,含1中的至少一个的化合物,单元从至少一种酚类化合物,甲醛和与芳族胺的烷基单元,含有至少一个伯氨基的至少一个邻位的氢。 据汉阳称,芳香胺与烷基甲酸酯反应生成烷氧基甲基中间体化合物。 然后中间体化合物与苯酚反应生成苯并恶嗪化合物。 根据另一个实施方案,苯并吡唑化合物通过在一个反应​​步骤中使芳族胺与烷基甲酸和苯酚反应而形成。 还公开了分离通过使芳族胺与烷基型单体反应形成的烷氧基甲基化合物的方法。 分离的烷氧基甲基化合物可用作后续反应中的反应物。
    • 5. 发明公开
    • 축합 2환식 화합물
    • 熔融双相化合物
    • KR1020100046230A
    • 2010-05-06
    • KR1020107004381
    • 2008-07-31
    • 미쓰비시 타나베 파마 코퍼레이션
    • 다카하시요이치아와이노부마사아카츠카히데노리가와구치다카유키이이지마도루
    • C07D265/16C07D311/58A61P43/00A61K31/353
    • C07D265/16C07D311/20C07D311/58C07D311/96C07D405/14C07D413/04
    • Disclosed is a novel fused bicyclic compound [I] shown below, which has affinity for a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agent or the like. Specifically disclosed is a compound represented by the formula [I] or a pharmacologically acceptable salt thereof. [I] wherein the ring A represents a benzene ring which is fused with the adjacent heterocyclic 6-membered ring and has a substituent R, and which may have a substituent other than R; Rrepresents an alkylsulfonylamino group or the like; Rand R(a) independently represent a hydrogen, an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c) together with the adjacent carbon atom, form a cycloalkyl; X represents =N-, =C(R)-or-CH(R)-; Rrepresents (a) a hydrogen, (b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) an alkanoyl, (h) a carbamoyl or (i) a cycloalkenyl; Ar represents a substituted or unsubstituted aromatic cyclic group; and a dotted line means the presence or absence of a double bond.
    • 公开了以下所示的新的稠合双环化合物[I],其对于皮肤激素受体(MR)具有亲和性,并且可用作抗高血压剂等。 具体公开的是由式[I]表示的化合物或其药理学上可接受的盐。 [I]其中环A表示苯环,其与相邻的杂环6元环稠合且具有取代基R,并且可以具有除R以外的取代基; R表示烷基磺酰基氨基等; 烷基R(a)独立地表示氢,烷基或取代或未取代的芳基,(b)一起形成氧代,或(c)与相邻碳原子一起形成环烷基; X表示= N-,= C(R) - 或-CH(R) - ; R代表(a)氢,(b)氰基,(c)卤素,(d)烷基,(e)烯基,(f)环烷基,(g)烷酰基,(h)氨基甲酰基或( i)环烯基; Ar表示取代或未取代的芳族环状基团; 而虚线表示存在或不存在双键。
    • 10. 发明公开
    • 안정화제로서의 다핵 페놀계 화합물의 용도
    • 多元酚类化合物作为稳定剂的使用
    • KR1020130100214A
    • 2013-09-09
    • KR1020137020930
    • 2007-02-21
    • 바스프 에스이
    • 란게아르노마흐헬무트라쓰한스페터포셀트디에트마르
    • C10L1/233C10M133/48C07D265/16C10L10/18
    • C10M159/12C07C217/58C07D265/16C08G61/12C08G61/122C08G61/124C08G61/125C08G61/126C08K5/3437C10L1/2225C10L1/233C10L1/238C10L10/18C10L2230/081C10L2230/086C10M133/48C10M149/12C10M2207/023C10M2215/225C10M2217/043C10N2230/10
    • Polynuclear phenolic compounds (Q) with up to 20 benzene nuclei per molecule obtained by the reaction of tetrahydrobenzoxazine compound (I) with one or more phenol compound (II) or one or more another tetrahydrobenzoxazine are used as stabilizers for stabilizing inanimate organic materials against the effects of light, acid and heat. Polynuclear phenolic compounds (Q) with up to 20 benzene nuclei per molecule obtained by the reaction of tetrahydrobenzoxazine compounds of formula (I) with one or more phenol compound of formula (II) or one or more another tetrahydrobenzoxazine are used as stabilizers for stabilizing inanimate organic materials against the effects of light, acid and heat. R 1>1-3000C hydrocarbon which may be interrupted by one or more heteroatom O, S and/or NR 6>; R 6>H or 1-4C alkyl; R 2>, R 3>, R 5>H, OH, or 1-3000C hydrocarbyl which may be interrupted by one or more O, S and/or NR 6>; R 4>H, OH, 1-3000C hydrocarbyl which may be interrupted by one or more O, S and/or NR 6> or a tetrahydrobenzoxazine group of formula (Z); or R 2>+R 3>, R 3>+R 4>, R 4>+R 5>+structure attached to benzene core of formula OCH 2NR 13>CH 2a second tetrahydrooxazine ring; or R 2>+R 3>, R 3>+R 4>, R 4>+R 5> with structure attached to benzene core of formula -O-CH 2-NR 13>-CH 2 or -OCH 2-NR 14>-CH 2- : a second or third tetrahydrooxazine ring; R 7>H, OH, 1-3000C hydrocarbyl which may be interrupted by one or more O, S and/or NR 6>, or a residue derived from (I); R 8>, R 10>H, OH, or 1-3000C hydrocarbon which may be interrupted by one or more O, S and/or NR 6>; R 9>H, OH, 1-3000C hydrocarbyl which may be interrupted by one or more O, S and/or NR 6>, or a phenol group of formula (Za); R 15>H or a residue derived from (I); R 11>, R 12>H or 1-10C-alkyl; and R 13>, R 14>1-3000C hydrocarbyl which is interrupted by one or more O, S and/or NR 6>. Provided that at least one of R 1>-R 10>, R 13> or R 14> is 13-3000C hydrocarbyl and the rest of R 1>-R 10>, R 13> or R 14> , when they are hydrocarbyls, are 1-20C. Independent claims are included for: (1) a turbine fuel composition comprising a turbine fuel (jet fuel) and at least (Q); (2) an additive concentrate for turbine fuels comprising at least (Q), a diluent and optionally at least an additive; (3) a lubricant composition, comprising at least (Q); (4) (Q) obtained by the above process; (5) an oligo- and poly-tetrahydro benzoxazine of formula (III) where n = 0-18; (6) a binuclear phenolic compound of formula (IV); and (7) a trinuclear phenolic compound of formula (V). R 2a>-R 5a>, R 8a>-R 10a>= H or 1-3000C hydrocarbon, which may be interrupted by one or more O, S and/or NR 6>. [Image] [Image] [Image] [Image] [Image]